going up

Real estate giant to open another downtown Houston coworking hub

Hines announced another flexible office space planned for downtown. Image courtesy of Hines

A new downtown Houston skyscraper that's on the rise and expected to be completed by the end of the year will offer flexible office space.

Texas Tower will feature The Square, Hines' flexible office product, the international real estate firm announced with Ivanhoé Cambridge. The 18,000-square-foot space will provide "elevated level of service and amenitization akin to a hospitality environment," according to a news release from Hines.

"We recognize the way our tenants conduct business is rapidly changing. The Square at Texas Tower will provide the highest quality flexible work experience in the market supported by an unparalleled dedication to service and integrity. Its offerings accommodate tenants' temporary teams, task forces, and expansions, and welcomes collaboration and variability," says Hines Senior Managing Director John Mooz in the release.

The Square is scheduled to open in early 2022 in the LEED Platinum office building that's being designed by Pelli Clarke Pelli. The flexible space is a result of a collaboration between Hines and Montreal-based firm, Ivanhoé Cambridge.

"We are thrilled to offer this signature workplace service in Texas Tower," says Jonathan Pearce, executive vice president of leasing and development, office and industrial at Ivanhoé Cambridge. "We have listened to our tenants and understand their need for flexibility of service, duration and built environment. As owner of Texas Tower and long-standing partners with Hines, we thrive to put forward innovative solutions such as The Square, to elevate and support the user experience of our customers and their employees' engagement, attraction, retention, and development."

Hines introduced its coworking concept — Hines² — a few years ago. Hines² already is up and running at two locations: 717 Texas, a 33-story Class A office tower in Houston, and The Kearns Building, a 10-story office building in Salt Lake City. As Hines looks to continued expansion, future cities may include Atlanta, Chicago, San Francisco, Washington, DC, and London, per the release.

The Square's first Houston location opened in 2020 at 717 Texas Ave. Image courtesy of Hines

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted